Replimune Group (NASDAQ:REPL) Shares Down 3.5% – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL) shares were down 3.5% during mid-day trading on Friday . The stock traded as low as $13.14 and last traded at $13.27. Approximately 92,520 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 869,392 shares. The stock had previously closed at $13.75.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on REPL shares. HC Wainwright increased their price target on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday. BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $19.14.

Replimune Group Price Performance

The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The business’s 50 day simple moving average is $12.18 and its two-hundred day simple moving average is $11.28. The stock has a market capitalization of $905.88 million, a P/E ratio of -4.35 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts forecast that Replimune Group, Inc. will post -2.88 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several hedge funds have recently added to or reduced their stakes in REPL. Charles Schwab Investment Management Inc. raised its holdings in shares of Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after purchasing an additional 52,498 shares during the period. Geode Capital Management LLC lifted its position in shares of Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the last quarter. Barclays PLC grew its stake in shares of Replimune Group by 165.5% during the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after acquiring an additional 98,791 shares during the period. LMR Partners LLP increased its holdings in Replimune Group by 145.8% in the 3rd quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock worth $904,000 after acquiring an additional 48,920 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after acquiring an additional 53,313 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.